DavidHenry MichaelSteffinMDStem Cell Transplant/Immunotherapy
Pediatric Hematology & Oncology • Houston, TXAssistant professor performing clinical research in Phase 1 CAR T cell trials for pediatric solid tumors, with a clinical focus in Hematopoietic Stem Cell Transplantation
Dr. Steffin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6701 Fannin St Ste 1510
Clinical Care Center Texas Childrens Hospital
Houston, TX 77030Phone+1 832-822-4242
Education & Training
Baylor College of MedicineFellowship, Pediatric Stem Cell Transplant, 2018 - 2019- Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2015 - 2018
Maimonides Medical Center/Infants and Children's Hospital of BrooklynResidency, Pediatrics, 2012 - 2015
Technion-Israel Inst of Technology Faculty of MedicineClass of 2012
Certifications & Licensure
TX State Medical License 2015 - 2026- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors Start of enrollment: 2021 Dec 08
Publications & Presentations
PubMed
- Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.David Steffin, Nisha Ghatwai, Antonino Montalbano, Purva Rathi, Amy N Courtney
Nature. 2024-11-27 - Hematopoietic stem cell transplantation for B-thalassemia major with alemtuzumab.Luisanna M Sánchez, Anil George, Brian D Friend, Saleh Bhar, Ghadir Sasa
Pediatric Hematology and Oncology. 2024-05-01 - 1 citationsEighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for Neuroblastoma.Li Che-Hsing, Sandhya Sharma, Andras A Heczey, David H M Steffin, Chrystal U Louis
Research Square. 2024-04-11
Press Mentions
- Study Shows Long-Term Safety of Genetically Modified Immune Effector CellsMarch 31st, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
